Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06210594 · ClinicalTrials.gov registry record · Phase 4
Staph Intervention for Effective Local Defense
A Phase 4 study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
NCT06210594 is a Phase 4 study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 78 participants.
The verdict
NCT06210594, a Phase 4 study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
Study Summary
Indigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections. The goal of this clinical trial is to evaluate a community-informed approach to reduce carriage of SA. Participants will be assigned to education and household supplies for prevention of SA with and without a biomedical intervention. Researchers will compare SA carriage in the two groups.
Interventions
- COMBINATION_PRODUCT Mupirocin + Nozin + chlorhexidine gluconate
- BEHAVIORAL Education + Household supplies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-11-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06210594
The ClinicalTrials.gov registry entry for NCT06210594 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mupirocin + Nozin + chlorhexidine gluconate is the first listed.
NCT06210594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06210594 about?
NCT06210594 is a clinical study titled "Staph Intervention for Effective Local Defense". Indigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections. The goal of this clinical trial is to evaluate a community-informed approach to reduce carriage of SA. P...
What is the current status of trial NCT06210594?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2024-04-01. Estimated completion is 2025-11-14.
What interventions are being tested in trial NCT06210594?
The interventions under investigation include: Mupirocin + Nozin + chlorhexidine gluconate (COMBINATION_PRODUCT), Education + Household supplies (BEHAVIORAL).
Who is sponsoring clinical trial NCT06210594?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.